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OBJECTIVE: To compare the impact of a disease man-
agement program to routine care on quality and costs of
care in diabetic patients.
METHODS: A pre-/post-analysis was performed to eval-
uate a comprehensive multidisciplinary diabetes disease
management (DM) program implemented in a multispe-
cialty medical group. Eighty-two adults with diabetes
(Type I or II) and elevated glycohemoglobin levels were
co-managed by a nurse practitioner and an endocrinolo-
gist in a diabetes DM clinic. Evidence-based guidelines
were utilized to assist care. Only patients enrolled with
the medical group for one year prior to the intervention
were deemed eligible for analysis. Quality of care was
evaluated by comparing glycosylated hemoglobin values
and the documented performance of preventive measures
in the year prior to and following the intervention. Dif-
ferences in visit costs are reported.
RESULTS: Glycohemoglobin levels changed by 0.8% in
the pre-intervention period and 	2.43% in the post-inter-
vention period (p  0.01). Statistically significant (p 
0.01) increases in rates of documented preventive measures
were noted as follows: foot exam (74% versus 99%); diet
counseling (49% versus 100%); blood pressure screening
(86% versus 100%); and exercise counseling (21% versus
100%). Changes in rates of influenza vaccination (30%
versus 41%); retinal examination (59% versus 68%); and
cholesterol screening (77% versus 74%) were not statisti-
cally significant. Visit costs increased from $211 per patient
in the pre-intervention period to $409 per patient in the
post-intervention period (p  0.01).
CONCLUSIONS: Implementation of a comprehensive
DM program for diabetic patients resulted in significant
reductions in glycohemoglobin levels and significant im-
provements in some, but not all, preventive care mea-
sures. Outpatient visit costs increased significantly as a
result of this intervention.
DM3
IMPLEMENTATION OF NATIONAL 
CHOLESTEROL GUIDELINES: 
A MULTIDISCIPLINARY APPROACH TO 
HYPERLIPIDEMIA DISEASE MANAGEMENT
Borenstein J, Saltiel M, Kaye S, Wright N, Graber G, Deutsch 
S, Weingarten S
Cedars-Sinai Health System, Los Angeles, CA, USA
National Cholesterol Education Program (NCEP) guide-
lines establish target levels for low density lipoprotein
(LDL) based on risk factors for coronary heart disease
(CHD). Achieving these goals in clinical practice is chal-
lenging, but has been shown to significantly reduce cardio-
vascular morbidity and mortality.
OBJECTIVE: This study was conducted to measure im-
provements in cholesterol control through implementa-
tion of national guidelines, utilizing a multidisciplinary
approach to hyperlipidemia disease management.
METHODS: A pre-/post-design was used to analyze the ef-
fectiveness of a pharmacist-run hyperlipidemia disease
management clinic in a staff-model medical group, enroll-
ing both managed care and fee-for-service patients (n 
203) with LDL levels exceeding NCEP goals. Patients were
identified from administrative data and primary care physi-
cian (PCP) referral. LDL goals were established in accor-
dance with NCEP guidelines. Patients were divided into
primary and secondary CHD prevention groups. Evidence-
based treatment guidelines were used to direct care, with
dietician and PCP consults at the pharmacists’ discretion.
RESULTS: By intention-to-treat analysis both primary
and secondary prevention groups had statistically signifi-
cant improvements in total cholesterol (	28 mg/dL and
	33 mg/dL, respectively, p  0.01), LDL (	26 mg/dL
and 	31 mg/dL, respectively, p  0.01), triglycerides
(	22 mg/dL and 	47 mg/dL, respectively, p  0.01) and
high density lipoprotein (3.3 mg/dL and 4.2 mg/dL,
respectively, p  0.01). Fifty-one percent of patients
reached their NCEP defined LDL goal. There was no sig-
nificant difference in percentage of patients achieving
goal LDL levels among the different treatment groups.
Medication costs increased for the secondary prevention
group ($9.32, p  0.01), decreased slightly for the pri-
mary prevention group (	$0.66, p  NS).
CONCLUSIONS: A multidisciplinary approach to hy-
perlipidemia disease management can provide significant
improvements in cholesterol control.
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COST-EFFECTIVENESS OF OCCUPATIONAL 
THERAPY ON HEALTHY ELDERLY PEOPLE
Luo R, Hay J, Clark F, Azen S, Liu G
University of Southern California, Los Angeles, CA, USA
The number of elderly Americans has increased dramati-
cally in recent years, and this trend will continue. It is criti-
cal to identify cost-effective interventions to promote the
general health of elderly people.
OBJECTIVE: To evaluate the cost-effectiveness of pre-
ventive occupational therapy on healthy elderly people.
METHODS: One hundred sixty-three individuals from
government subsidized senior apartments were random-
ized into three experimental conditions: individuals in the
occupational therapy group received 2 hours per week of
group-based intervention and 1 hour per month of indi-
vidual-based intervention; individuals in the social group
engaged in social activities, such as dancing, watching
movies, and community outings; and participants in the
control group remained untreated. The trial period con-
sisted of a 9-month treatment phase and a 6-month follow-
up phase. Monthly telephone interviews were conducted
to collect information on patients’ healthcare utilization.
In addition, all participants were evaluated at pre-test,
post-test, and follow-up stages by using the SF-36 ques-
tionnaire. The Current Procedural Terminology and the
Diagnosis Related Group databases were used to convert
the utilization information into costs. A prediction model
was used to compute each patient’s quality of well-being
index by using the SF-36 domain scores.
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RESULTS: Compared to the combined control groups, sig-
nificant long-term benefit attributable to the occupational
therapy intervention was found for six of the eight SF-36
domain scores: body pain, role functioning, vitality, social
functioning, role emotional, general mental health (p 
0.05). When we compared the occupational therapy group
with the combined control group, the incremental cost-
effectiveness ratio was $17,476 per QALY. Sensitivity anal-
yses confirmed that these quantitative results were robust.
OUTCOMES RESEARCH METHODS
RM1
CONTROLLING FOR SIMULTANEITY BIAS IN 
OUTCOME STUDIES USING PANEL DATA
Luo R, Hay J, Hsiao C
The University of Southern California, Los Angeles, CA, USA
In outcome studies, healthcare costs and health status are
two focuses of primary interest. These two variables in-
teract with each other: change in health status results in
healthcare utilization and healthcare utilization has impact
on health status. This interaction necessitates a statistical
simultaneous modeling. Ignoring such endogeneity could
lead to inappropriate conclusions. Often, outcomes data
from clinical trials consist of panel data in which out-
comes are repeatedly measured over time. The nature of
panel data complicates statistical modeling to control for
this endogeneity bias.
OBJECTIVE: To present a statistical model and an esti-
mation procedure that are most suitable to tackling the
endogeneity between healthcare costs and health status
by using panel data from clinical trials.
METHOD: A simultaneous error-component model is
established as:
<1>
<2>
where
The dependent variable and are the health expenditure and
health status of individual i (i  1, 2,. . ., N) at time t (t 
1,. . ., T); Xit is the vector of the common exogenous vari-
ables in both the cost and health equations; z1it is the vec-
tor of explanatory variables included in the cost equation
but not the health equation; z2it is the vector of explana-
tory variables included in the health equation but not the
cost equation.  are the unknown parameters; v1it and v2it
and are the unobserved disturbances which consist of 
i,
the component from an individual unit, t, the component
from a time period, uit, the independently identically dis-
tributed random disturbance. Given the structure of the
disturbances in the model, we propose the error-compo-
cit hitβ11 Xitβ12 zlitβ13 vlit+++=
hit citβ21 Xitβ22 z2itβ23 v2it+ + +=
v1it α1i λ1t u1it+ +=
v2it α2i λ2t u2it+ +=
nent three-stage least-squares method to estimate this
model.
IMPLICATION: This paper provides an example of
modeling costs and health status simultaneously using
panel data from clinical trials.
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COSTS OF HEALTHCARE FOR 8 YEARS PRIOR 
TO RECOGNITION OF TYPE 2 DIABETES (DM2)
Nichols GA, Brown JB
Center for Health Research, Portland, OR, USA
Type 2 Diabetes and its complications lead to higher
medical care costs, beginning at diagnosis and continuing
throughout life. But little is known about healthcare ex-
penditures and utilization prior to recognition of DM2.
We identified all members of Kaiser Permanente North-
west Region, a nonprofit HMO, diagnosed with DM2 in
1988 through 1995, and matched each of them to an
HMO member without DM based on age, gender, and
eligibility. We then observed outpatient, pharmaceutical,
and inpatient costs in the 8 years prior to diagnosis and
calculated incremental costs as the difference between
DM2s and their matched controls. Total costs for DM2s
and their matched controls were relatively flat 4 to 8 years
prior to diagnosis of DM2; incremental costs were not sig-
nificantly different from zero in those years. In the 3 years
immediately before diagnosis, however, DM2 costs rose
while control costs remained flat. By this measure, DM2
appears to cause significant excess total costs, starting
about 3 years prior to diagnosis. Considered on their own,
though, outpatient and pharmacy costs each exceeded
control costs during all 8 pre-diagnostic years. The major-
ity of incremental costs were for outpatient visits (62%).
We conclude that DM2 begins causing greater health ex-
penditures at least 8 years before diagnosis.
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THE USE OF ABCIXIMAB FOR PERCUTANEOUS 
TRANSLUMINAL CORONARY ANGIOPLASTY 
PATIENTS ENROLLED IN MANAGED CARE 
ORGANIZATIONS
Lage M1, Barber B2, Bowman L2, Ball D2, Bala M3
1Miami University, Oxford, OH, USA; 2Eli Lilly and Company, 
Indianapolis, IN, USA; 3Centocor Inc., Malvern, PA, USA
Per-person medical costs by year prior to diagnosis of DM2
No. of
cases
Pre-DX
year
DM2
costs ($)
Control
costs ($)
Incremental
costs ($)
Percent
incremental (%)
708 	8 1774 1712 62 3%
1493 	7 2144 1767 377 18%
2397 	6 1872 1792 80 4%
3323 	5 2208 2005 203 9%
4269 	4 2238 2044 194 9%
5327 	3 2474 1911 563 23%
6490 	2 2536 1978 558 22%
8685 	1 2819 1949 870 31%
